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Background: The associations between urine uric acid excretion (UUAE) and chronic kidney disease (CKD)/
atherosclerosis have not been investigated. Our aims were to investigate the relationships between UUAE and
CKD and carotid atherosclerotic lesions in hospitalized Chinese patients with type 2 diabetes.
Methods: This was a cross-sectional study that was conducted with 2627 Chinese inpatients with type 2 diabetes.
UUAE was determined enzymatically using a single 24-h urine collection. The subjects were stratified into quartiles
according to their UUAE levels. Carotid atherosclerotic lesions, including carotid intima-media thickness (CIMT),
plaque and stenosis, were assessed by Doppler ultrasound. Both CKD and carotid atherosclerotic lesions were
compared between the UUAE quartile groups.
Results: After adjustment for confounding factors, there was a significant decrease in the prevalence of CKD in
the patients with type 2 diabetes across the UUAE quartiles (16.9%, 8.5%, 5.9%, and 4.9%; p < 0.001). Multiple
logistic regression analyses revealed that the UUAE quartiles were significantly and inversely associated with the
presence of CKD (p < 0.001). Compared with the diabetics in the highest UUAE quartile, those in the lowest
quartile exhibited a nearly 4.2-fold increase in the risk of CKD (95% CI: 2.272-7.568; p < 0.001). The CIMT value
(0.91 ± 0.22 mm for the diabetics with CKD and 0.82 ± 0.20 mm for the diabetics without CKD, p = 0.001) and the
prevalence of carotid plaques (62.1% for the diabetics with CKD and 41.8% for the diabetics without CKD, p = 0.025)
were significantly higher in the diabetics with CKD than in those without CKD. However, there was no obvious
difference in carotid atherosclerotic lesions across the UUAE quartiles after controlling for the confounding factors.
Conclusions: Decreased UUAE was closely associated with the presence of CKD but not with carotid atherosclerotic
lesions in hospitalized Chinese patients with type 2 diabetes. Our results suggest that UUAE is an independent risk
factor for CKD in type 2 diabetes. In selected populations, such as patient with type 2 diabetes, the role of uric acid in
atherosclerosis might be the result of other concomitant atherosclerotic risk factors, such as CKD.
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In recent decades, accumulated clinical and epidemio-
logical studies have confirmed the positive correlation
between serum uric acid (SUA) and chronic kidney
disease (CKD). For example, a large follow-up clinical
trial that included 177,570 patients reported that the
subjects in the highest SUA quartile exhibited a 2.14-fold
increase in the risk for CKD compared with those in the
lowest SUA quartile over 25 years [1].
In contrast, many studies have also investigated the rela-
tionship between SUA and atherosclerosis. However, un-
like the association between SUA and CKD, which has
been repeatedly demonstrated, the correlation between
SUA and atherosclerosis remains controversial. For ex-
ample, a previous study indicated that SUA is an inde-
pendent risk factor for carotid atherosclerosis in type 2
diabetes [2]. However, another study by Iribarren et al.
reported that the correlation between SUV levels and
carotid intimal-medial thickness (CIMT) did not re-
main significant after controlling for other risk factors
for atherosclerosis [3]. Similarly, in our previous study,
we also found no significant association between SUA
levels and atherosclerotic lesions in type 2 diabetes [4].
Furthermore, although a number of studies have assessed
the relationships between SUA levels and CKD/atheroscler-
osis, the associations of urine uric acid excretion (UUAE)
with CKD and atherosclerosis have not been investigated in
general or diabetic populations. To date, epidemiological
data are absent regarding these relationships in patients
with type 2 diabetes.
Therefore, the aim of the present study was to exam-
ine the associations of UUAE with CKD and carotid
atherosclerosis in hospitalized Chinese patients with
type 2 diabetes. To our knowledge, this is the first
study to investigate the associations of UUAE with
CKD and atherosclerosis in type 2 diabetes.
Methods
Subjects and study design
The present study was cross-sectional and was partly based
on data from our previous studies [4-8]. In brief, from
January 2007 to June 2009, 3598 patients with type 2 dia-
betes who were consecutively hospitalized in our depart-
ment were observed. All patients received a diabetic diet
and avoided excessive purine intake and alcohol consump-
tion after admission to the hospital. Of the 3598 subjects,
the UUAE data from 3007 patients were available. The fol-
lowing patients were excluded from the study: those taking
any drug that interfered with uric acid metabolism,
such as losartan, allopurinol and furosemide; patients
with underlying renal disease inconsistent with the
diabetes, such as glomerulonephritis and autoimmune
kidney disease; and patients who had not undergone
carotid ultrasound examination or had incomplete clinicaldata. Ultimately, 2627 patients were included in the
final analyses.
All subjects were interviewed to obtain their histories
of hypertension (HTNs), cardio-cerebrovascular events
(CCEs), use of lipid-lowering drugs (LLDs), use of anti-
hypertensive agents (AHAs), alcohol consumption and
smoking habits. The HTNs, CCEs and smoking and alco-
hol drinking histories were defined according to the cri-
teria utilized in our previous research [4-9]. This study
was approved by the ethics committee of the Shanghai
Jiao Tong University Affiliated Sixth People’s Hospital. All
subjects completed a written informed consent form
before entering the study.
Physical examination and laboratory measurements
The physical examinations and laboratory measurements
have been described in our previous studies [4-9]. Briefly,
height, weight, waist circumference, hip circumference,
and blood pressure were examined in all patients. Blood
samples were obtained after an overnight fast and 2 h after
breakfast measurements of glycosylated hemoglobin A1C
(HbA1c), fasting plasma glucose (FPG), 2-h postprandial
plasma glucose (2 h PPG), fasting C-peptide (FCP), 2-h
postprandial C-peptide (2 h PCP), total triglycerides
(TTG), total cholesterol (TC), high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C), alanine aminotransferase (ALT), creatinine (Cr),
serum uric acid (SUA), and C-reactive protein (CRP).
Based on the plasma glucose and serum C-peptide levels,
the homeostasis model assessment for insulin resistance
(HOMA2-IR) and insulin sensitivity (HOMA2 %S) values
were calculated using the HOMA2 calculator version
2.2.3 [10,11].
Currently, the simplest and most common approach
that is applied in clinical practice to determine the renal
excretion of uric acid is the measurement of urinary uric
acid output over a 24-h period [12]. Therefore, a single
24-h urine sample was collected, and the 24-h UUAE was
determined by enzymatic methods. The 24-h urinary albu-
min excretion (UAE) was calculated as the mean of the
values obtained from three separate early morning urine
samples during the period of hospitalization. The esti-
mated glomerular filtration rate (eGFR) was calculated
using the following equation for Chinese individuals:
eGFR = 175× (serum creatinine)-1.234× (age)-0.179 (×0.79 if
female) [13]. CKD was defined as an eGFR less than
60 mL/min/1.73 m2 and/or an UAE ≥ 300 mg/24 h [14] .
Ultrasonography measurements
Carotid atherosclerotic lesions including CIMT, athero-
sclerotic plaque and stenosis were measured by Doppler
ultrasound as described previously in detail [5,7,8]. The
definitions of CIMT, carotid atherosclerotic plaque and
stenosis have also been described in detail in our
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surements of the carotid arteries have also been reported
in our previous studies [7,8].
Statistical analyses
SPSS 15.0 for Windows software was used for the stat-
istical analyses. P values <0.05 were considered to be
statistically significant. The data are expressed as ei-
ther the means ± the S.D. or as percentages or medians
(interquartile range 25%-75%). One-way ANOVAs
with LSDs were used for continuous variables with
normal distributions for comparisons across multipleTable 1 Characteristics of the subjects
Variables Q1 (n = 655) Q2 (n = 658)
UUAE(μmol/24 h) <2235 2235-2848
Male (n, %) 315 (48.1%) 337 (51.2%)
Age (years) 63 ± 13 60 ± 12
*DD (months) 108(48–168) 84(12–144)
Smoking (n, %) 146(22.29%) 148(22.49%)
Alcohol (n, %) 68(10.38%) 88(13.37%)
Hypertension (n, %) 376(57.4%) 333(50.6%)
CCEs (n, %) 117(17.90%) 84(12.80%)
LLDs (n, %) 170(25.95%) 199(30.24%)
AHAs (n, %) 346(52.82%) 296(44.98%)
SBP (mmHg) 133 ± 18 133 ± 18
DBP (mmHg) 78 ± 9 80 ± 10
BMI(kg/m2) 23.9 ± 3.6 24.4 ± 3.3
WHR 0.90 ± 0.07 0.91 ± 0.06
*FPG(mmol/l) 7.3(5.9-9.4) 7.4(6–9.6)
*2 h PPG(mmol/l) 12.9(9.3-16.4) 13.4(10–16.8)
HbA1C (%) 9.2 ± 2.6 9.1 ± 2.5
*FCP (ng/mL) 1.41(0.82-2.38) 1.59(0.94-2.28)




TC(mmol/l) 4.66 ± 1.13 4.75 ± 1.24
HDL-C(mmol/l) 1.16 ± 0.31 1.15 ± 0.31
LDL-C(mmol/l) 3.03 ± 0.95 3.14 ± 1.01
*ALT (U/l) 17(12–25) 18(13–28)
*Cr (μmol/l) 67(55–86) 68(56–80)
*SUA (μmol/l) 302(249–370) 314(256–380)
*UAE (mg/24 h) 11(5.9-45.7) 10.2(6.2-24.8)
*eGFR (ml/min/1.73 m2) 103(80–129) 106(88–129)
*CRP (mg/l) 1.16(0.46-3.49) 1.10(0.49-2.77)
Values are expressed as the mean±S.D, median with interquartile range, or percent
*Non-normal distribution of continuous variables.
P-value: The p-values were not adjusted for age and sex for the trend.
*P-value: The *p-values were adjusted for age and sex for the trend.groups. For continuous variables with skewed distribu-
tions, Mann–Whitney U tests and Kruskal-Wallis H
tests were used. The χ2 test was used to compare the
prevalence data. The partial correlations were used to
determine the relationships between the UUAE and the
variables. The general linear model was used to compare
the means of the continuous variables and the associations
between the UUAE quartiles and CIMT when control-
ling for other factors. Binary logistic regression analysis
was performed to examine the associations of the UUAE
quartiles with the presence of CKD, carotid plaque and
stenosis.Q3 (n = 657) Q4 (n = 657) p value *p value
2849-3606 >3606 — —
385 (58.6%) 439 (66.8%) <0.001 <0.001
57 ± 12 54 ± 11 <0.001 <0.001
72(12–120) 60(12–120) <0.001 0.001
218(33.18%) 254(38.66%) <0.001 0.004
105(15.98%) 156(23.74%) <0.001 0.008
336(51.10%) 345(52.5%) 0.056 0.003
86(13.10%) 64(9.70%) <0.001 <0.001
191(29.07%) 253(38.51%) <0.001 <0.001
312(47.49%) 305(46.42%) 0.031 0.004
131 ± 17 131 ± 16 0.015 0.295
81 ± 10 81 ± 10 <0.001 <0.001
25.0 ± 3.2 26.2 ± 3.3 <0.001 <0.001
0.91 ± 0.06 0.93 ± 0.06 <0.001 <0.001
7.7(6.2-9.5) 8.3(6.8-10.1) <0.001 0.009
13.2(10.3-16.5) 14.1(10.8-17.5) <0.001 <0.001
9.0 ± 2.4 9.1 ± 2.2 0.836 0.266
1.68(1.15-2.41) 1.92(1.31-2.8) <0.001 <0.001
3.86(2.3-5.34) 4.21(2.61-5.63) <0.001 <0.001
1.5(1.10-2.1) 1.8(1.2-2.5) <0.001 <0.001
65.2(47.45-91.5) 56.1(40.4-81.5) <0.001 <0.001
1.43(1.01-2.08) 1.72(1.17-2.59) <0.001 <0.001
4.66 ± 1.07 4.80 ± 1.14 0.068 0.065
1.10 ± 0.29 1.05 ± 0.29 <0.001 <0.001
3.08 ± 0.88 3.13 ± 0.95 0.163 0.168
20(14–32) 25(16–41) <0.001 <0.001
66(56–79) 66(56–78) 0.058 <0.001
304(255–372) 320(267–380) 0.005 0.087
9.7(6.3-21.9) 13(7.6-32.8) <0.001 <0.001
111(93–133) 113(98–135) <0.001 0.046
1.09(0.48-2.34) 1.15(0.51-2.81) 0.644 0.120
ages.
Table 2 Correlations between UUAE and other
parameters in the patients with type 2 diabetes








2 h PPG 0.077 <0.001
HbA1C −0.014 0.517
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Characteristics of the subjects according to UUAE
quartiles
The clinical characteristics of the subjects grouped ac-
cording to the UUAE quartiles are presented in Table 1.
The patients were stratified into quartiles based on the
UUAE levels with the cutoff limits of <2235, 2235–2848,
2849–3606, and >3606 μmol/24 h. After controlling for
age and sex, the diabetics in the higher UUAE quartiles
were more likely to be male, younger, smokers and
drinkers; have shorter durations of diabetes (DD); have
higher DBP, BMI, WHR, FPG, 2 h PPG, FCP, 2 h PCP,
HOMA2-IR, TTG, ALT, and eGFR; and have lower
HOMA2-%S, HDL-C and Cr.FCP 0.129 <0.001
2 h PCP 0.127 <0.001
HOMA2-IR 0.111 <0.001







Cr −0.125 <0.001Associations between UUAE levels and clinical parameters
The associations between UUAE levels and the clinical
parameters are shown in Table 2. After adjusting for age,
sex and DD, the partial correlations analyses demon-
strated strongly positive correlations of UUAE levels
with SBP, DBP, BMI, WHR, FPG, 2 h PPG, FCP, 2 h
PCP, HOMA2-IR, TTG, TC, ALT, eGFR, and CRP, and
significantly negative correlations between UUAE levels
and age (controlling for sex and DD), DD (controlling




All correlation coefficients were calculated after adjusting for age, sex and
duration of diabetes.Comparison of CKD among the UUAE quartiles
Figure 1 demonstrates the comparison of CKD among
the UUAE quartiles in patients. After controlling for age,
sex, and DD, there was a significantly decreasing trend
in the prevalence of CKD in patients across the UUAE
quartiles (16.9%, 8.5%, 5.9%, and 4.9%, respectively, p <
0.001 for the trend; Figure 1A). Furthermore, the UUAE
levels were obviously reduced in the diabetics with CKD
compared to those without CKD (p < 0.001) (Figure 1B).
Interestingly, the UUAE levels gradually decreased with
the decreases in eGFR (p < 0.001; Figure 1C), and the
UUAE levels were significantly decreased in the diabetics
with UAEs ≥ 300 mg/24 h compared to those with
UAEs <30 mg/24 h and those with UAEs in the range
of 30–299 mg/24 h (p < 0.001; Figure 1D).Comparison of the carotid atherosclerotic lesions among
the UUAE quartiles
A comparison of the atherosclerotic lesions among the
UUAE quartile groups after adjustments for age, sex, and
DD is shown in Figure 2. There were no statistical associa-
tions between the UUAE quartiles and the carotid IMT
values (p = 0.736) and the prevalence of carotid plaques
(p = 0.938) and stenosis (p = 0.171) in type 2 diabetes
(Figure 2A, B and C).Associations of UUAE quartiles with CKD
Table 3 presents the associations between the UUAE
quartiles and the presence of CKD in type 2 diabetes.
After controlling for age, sex, DD, HTN, smoking, alco-
hol drinking, and the use of LLDs and AHAs (model 1),
the UUAE quartiles were independently associated with
a decreased prevalence of CKD (p < 0.001 for trend).
After additional adjustments for SBP, DBP, WHR and
BMI (model 2) and for ALT, TC, TTG, LDL-C, HDL-C,
CRP, HbA1C, FPG, 2 h PPG, FCP, 2 h PCP, HOMA2-IR,
and HOMA %S (model 3) and for SUA (model 4), the
UUAE quartiles retained an independent association
with a decreased prevalence of CKD (all p <0.001 for the
trends in model 2, model 3, and model 4).
Comparisons of carotid atherosclerotic lesions between
the diabetics with and without CKD
The comparisons of carotid atherosclerotic lesions be-
tween the diabetics with and without CKD are illustrated
in Figure 3. After adjusting for age, sex, and DD, the
CIMT values (0.91 ± 0.22 mm for the diabetics with
Figure 1 Comparison of CKD among the UUAE quartiles. (A) Comparison of the prevalence of CKD among the UUAE quartile groups after
adjusting for age, sex, and DD. The P values for the trends were <0.001. (B) Comparison of the UUAE levels between the diabetics with and
without CKD after adjusting for age, sex, and DD. The P value was <0.001. (C) Comparison of UUAE levels among the different eGFR levels after
adjusting for age, sex, and DD. The P values for the trends were <0.001. (D) Comparison of UUAE levels among the different UAE levels after
adjusting for age, sex, and DD. The P values for the trends were <0.001.
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p = 0.001) and the prevalence of carotid plaque (62.1%
for the diabetics with CKD and 41.8% for the diabetics
without CKD, p = 0.025) were significantly higher in the
diabetics with CKD than in those without CKD.Discussion
Recent evidence has supported uric acid as a potential
mediator that is associated with CKD; however, the inde-
pendence of the association between uric acid and athero-
sclerosis has been controversial. Furthermore, although a
number of studies have focused on the associations of
SUA with CKD and atherosclerosis, few investigators have
investigated the relationships between UUAE and CKD/
atherosclerosis in nondiabetic and diabetic populations.
Therefore, we performed this cross-sectional study of
the associations between UUAE and CKD/atheroscler-
osis in hospitalized type 2 diabetics. Our results strongly
suggested that decreased UUAE is an independent risk
factor for CKD but not for carotid atherosclerotic lesions
in type 2 diabetes.The factors controlling UUAE in type 2 diabetes
The mechanisms of controlling UUAE are largely un-
known in type 2 diabetes. Generally, UUAE levels are
mainly dependent on tubular secretion and postsecre-
tory reabsorption [15]. The renal excretion of uric acid
is a complex process regulated by genetic and environ-
mental factors. The primary capacity of the renal excre-
tion of uric acid might be of genetic origin. For example,
Emmerson et al. found that both urate clearance and the
fractional excretion of uric acid were more similar in
monozygotic twins than in dizygotic twins, which indi-
cates that genetic factors exert a key control on the renal
excretion of uric acid [16]. Furthermore, a previous study
demonstrated that polymorphisms in the N-terminus of
the hURAT1 gene are obviously associated with reduced
renal uric acid excretion in a German Caucasian popu-
lation [17]. Therefore, decreased UUAE in type 2 dia-
betics with CKD might be associated with a genetic
predisposition.
In addition to genetic factors, other factors might influ-
ence the renal excretion of uric acid. For example, in
healthy humans, physiological hyperinsulinemia can reduce
Figure 2 Comparison of carotid atherosclerotic lesions among the
UUAE quartiles. (A) Comparison of the CIMT values among the
UUAE quartile groups after adjusting for age, sex, and DD. (B)
Comparison of the prevalence of carotid atherosclerotic plaques
among the UUAE quartile groups after adjusting for age, sex, and
DD. (C) Comparison of the prevalence of carotid atherosclerotic
stenosis among the UUAE quartile groups after adjusting for age,
sex, and DD.
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tion at the tubular levels, which might lead to an increase
in SUA levels [15,18]. Therefore, in healthy subjects, UUAEhas been shown to be inversely related to insulin resistance
and SUA [18]. However, in contrast to healthy subjects, in
our present study, the diabetic patients in the higher UUAE
quartiles were associated with reduced insulin sensitivity
and increased insulin resistance, which theoretically should
result in decreased UUAE. Indeed, patients with decreased
UUAE are typically associated with impaired renal function
and decreased rates of renal filtration, which might be at-
tributed to uric acid-mediated renal damage. Consistent
with our hypothesis, we observed an inreased eGFR among
the UUAE quartiles. Additionally, because of the inhibitory
effects of uric acid reabsorption in the kidney due to high
glucose levels, UUAE levels are often increased in patients
with diabetes, particularly in diabetes patients with poor
glucose control [19,20]. In accordance with this perspective,
we observed a positive correlation between UUAE and
blood glucose levels, and the blood glucose levels were
gradually elevated across the UUAE quartiles in type 2
diabetes.
Therefore, we speculated that decreased UUAE might
initially originate from genetic factors in type 2 diabetics
with CKD. Reduced UUAE led to impaired renal function,
which further aggravated the decreases in UUAE. Thus,
diminished UUAE was a risk factor for the development
and progression of CKD rather than a consequence of
impaired renal function.
The association between UUAE and CKD
More importantly, we observed a significant inverse asso-
ciation between UUAE and the presence of CKD in type 2
diabetics. A number of investigations have shown that an
elevated SUA level is an independent risk factor for CKD
in both the general population and the population with
type 2 diabetes [1,21-23]. For example, a 5-year follow-up
study demonstrated that every 1-SD increment in the
SUA level was obviously associated with a 21% increase in
the CKD in type 2 diabetic patients [23]. Furthermore,
two observational studies that were performed with type 2
diabetes patients revealed that even high-normal SUA was
also associated with albuminuria and impaired renal func-
tion [24,25]. Consistent with the results of these studies,
our results revealed that the prevalence of CKD substan-
tially increased with a decrease in UUAE in type 2 dia-
betes. Compared with the diabetics in the highest UUAE
quartile, the diabetics in the lower UUAE quartiles exhib-
ited a significantly higher risk of CKD. Moreover, the pa-
tients with either lower eGFR or higher UAE exhibited
lower UUAE levels, which indicated that decreased UUAE
might be related to the severity of CKD in type 2 diabetes.
The mechanisms underlying the association between
decreased UUAE and CKD remain to be elucidated. How-
ever, it has been speculated that the local accumulation of
uric acid in the kidney might be one of the mechanisms
that causes CKD. Decreased UUAE in type 2 diabetes
Table 3 Association of the UUAE quartiles with CKD
ORs (95% CI) P values
for trendQ4 Q3 Q2 Q1
Model 1 1 1.225 (0.742-2.021) 1.909 (1.183-3.083) 3.731 (2.375-5.861) <0.001
Model 2 1 1.437 (0.839-2.460) 2.313 (1.379-3.882) 4.423 (2.695-7.258) <0.001
Model 3 1 1.860(1.008-3.431) 2.198(1.187-4.070) 4.617 (2.559-8.330) <0.001
Model 4 1 1.785(0.948-3.359) 1.820(0.967-3.426) 4.147 (2.272-7.568) <0.001
Model 1: adjusted for age, sex, DD, HTN, smoking, alcohol drinking, and the use of LLDs and AHAs.
Model 2: further adjusted for SBP, DBP, WHR and BMI.
Model 3: further adjusted for ALT, TC, TTG, LDL-C, HDL-C, CRP, HbA1C, FPG, 2 h PPG, FCP, 2 h PCP, HOMA2-IR, and HOMA % S.
Model 4: further adjusted for SUA.
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ther than entering the blood circulation. In an uricase
gene-knockout mouse models, Wu et al. found that mouse
develop pronounced hyperuricemia, renal tubular crystal
deposition and renal failure [26], and these findings indi-
cate the a key role of uric acid in the pathogenesis of CKD.
More importantly, uric acid can exert direct effects on
renal tubules. A recent experimental study found that
uric acid can induce a phenotypic transition termed the
epithelial-to-mesenchymal transition (EMT) in renal
tubular cells and in the renal tubules of rats with hyperuri-
cemia [27], and this transition plays an important role in
pathogenesis of CKD. Furthermore, allopurinol signifi-
cantly inhibits uric acid-induced phenotypic changes and
leads to the amelioration of renal fibrosis [27]. Therefore,
uric acid accumulation in the kidney undoubtedly causes
the progression of kidney injury and reduced UUAE.
Reduced UUAE further aggravates kidney lesions.
The association of UUAE/CKD with carotid atherosclerotic
lesions
In contrast, there are no significant associations be-
tween UUAE and carotid atherosclerotic lesions in type
2 diabetes. Although no data about the association be-
tween UUAE and atherosclerosis are currently available,
debate continues regarding the relationship between SUA
levels and atherosclerosis in healthy individuals and pa-
tients with diabetes. Several studies have reported thatFigure 3 Comparison of carotid atherosclerotic lesions between the diabe
the diabetics with and without CKD after adjusting for age, sex, and DD. (B
between the diabetics with and without CKD after adjusting for age, sex,
stenosis between the diabetics with and without CKD after adjusting forhigh levels of SUA are associated with carotid athero-
sclerosis in both healthy and type 2 diabetic subjects
[2,28-31]. For example, Fukui et al. found a positive cor-
relation between SUA concentration and CIMT [28].
Similarly, Erdogan et al. also found that increased SUA
levels, even within the physiological range, are significantly
correlated with increased CIMT independently of other
cardiovascular risk factors in healthy adults [29].
However, several cross-sectional and epidemiological
follow-up studies, including our own study, have con-
cluded that SUA is not independently associated with
atherosclerosis or coronary heart disease [3,4,32-36].
For example, Iribarren et al. reported that the statisti-
cally significant association between SUA and CIMT
was lost after further adjustments for known risk fac-
tors for atherosclerosis [3]. Our own study also found
that SUA levels are associated with HTN and metabolic
syndrome but not with atherosclerosis in type 2 diabetes
[4]. Thus, the observed association between elevated SUA
levels and atherosclerosis might be a consequence of con-
comitant other cardiovascular risk factors, such as HTN
and metabolic syndrome [4,37]. Similar to the above
studies, we failed to observe an independent association
between UUAE and carotid atherosclerosis in type 2
diabetes in this study.
It has been demonstrated that atherosclerotic lesions
are accelerated in patients with CKD even in early stages
of renal dysfunction primarily due to a wide variety oftics with and without CKD. (A) Comparison of the CIMT values between
) Comparison of the prevalence of carotid atherosclerotic plaques
and DD. (C) Comparison of the prevalence of carotid atherosclerotic
age, sex, and DD.
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cular risk factors in the CKD population, such as aging,
HTN, dyslipidemia, increased oxidative stress, inflamma-
tion and vascular calcification [38]. Therefore, it is difficult
to determine whether CKD itself is independently related
to the increased prevalence of atherosclerosis in patients
with CKD. However, recent studies have strongly indi-
cated that CKD itself might be an independent risk factor
for atherosclerosis [39-42]. For example, one investigation
enrolled 4297 asymptomatic subjects undergoing coronary
CT angiography and reported that, after adjustment for
confounding factors, early CKD was an independent risk
factor for coronary atherosclerosis [42]. Furthermore, a
study performed in Chinese patients with type 2 diabetes
demonstrated that hypertension, dyslipidemia, and CKD
have cumulative effects on the burden of carotid plaques
[43]. Given the absence of an association between UUAE
and carotid atherosclerosis, we believe that in selected
populations, such as those with type 2 diabetes, the
pathogenetic roles of uric acid in the development and
progression of atherosclerosis might be indirect and
mediated by other cardiovascular risk factors, such as
CKD, HTN and metabolic syndrome. Therefore, the
role of uric acid in the development and progression
of atherosclerosis is ambiguous and requires further
clarification.
Although multiple risk factor interventions and some
medicines, such as liraglutide, can mitigate atherosclerotic
lesions in type 2 diabetes, none of the biomarkers that are
utilized, such as endothelial function parameters, can pre-
dict changes in the progression of atherosclerosis [44,45].
Additional risk factors related to atherosclerosis, such as
CKD, should be identified, and early interventions will be
useful for reducing future cardiovascular events in type 2
diabetes.Limitations
Several limitations of this study must be mentioned.
Because the participants were Chinese patients with
type 2 diabetes, the results might not be generalizable
to other populations. Additionally, due to the cross-
sectional nature of this study, we are not able to estab-
lish the causal relationship between decreased UUAE
and CKD. Prospective studies are needed to determine
the relationship between UUAE and CKD. Finally, the
examination of UUAE was determined by a single 24-h
urine collection rather than three successive collections.
Thus, the fluctuations of UUAE could not be minimized.
However, when a careful protocol is followed, and the pa-
tients strictly follow a standard diet, the difference in 24-h
uric acid excretion is very minor [46]. Furthermore, it
might be impractical to collect three urinary samples in
clinical practice.Conclusions
Our results suggest that decreased UUAE is independ-
ently associated with the presence of CKD but not with
carotid atherosclerosis in type 2 diabetes. Decreased
UUAE levels might serve as a simple and useful marker
for predicting the occurrence and progression of CKD in
type 2 diabetes. In selected populations, such as patients
with type 2 diabetes, the role of uric acid in atheroscler-
osis might result from other concomitant atherosclerotic
risk factors, such as CKD. Further study is required to
determine whether promoting UUAE represents a new
therapeutic target for the prevention of CKD in type 2
diabetes.
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